Cargando…

Detecting pioglitazone use and risk of cardiovascular events using electronic health record data in a large cohort of Chinese patients with type 2 diabetes

BACKGROUND: Pioglitazone may have a protective effect against cardiovascular disease risk among type 2 diabetes (T2D) patients, but evidence from China is lacking. This study investigated the association using electronic health records (EHR) data from a Chinese cohort of T2D patients. METHODS: All T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miao, Shumei, Dong, Xiao, Zhang, Xin, Jing, Shenqi, Zhang, Xiaoliang, Xu, Tingyu, Wang, Li, Du, Xianglin, Xu, Hua, Liu, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850402/ https://www.ncbi.nlm.nih.gov/pubmed/30597747 http://dx.doi.org/10.1111/1753-0407.12894

Ejemplares similares

Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk
por: Zou, Cong, et al.
Publicado: (2013)

Use and Customization of Risk Scores for Predicting Cardiovascular Events Using Electronic Health Record Data
por: Wolfson, Julian, et al.
Publicado: (2017)

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
por: Juurlink, David N, et al.
Publicado: (2009)

Analysis of treatment pathways for three chronic diseases using OMOP CDM
por: Zhang, Xin, et al.
Publicado: (2018)

Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study
por: Yang, Shao-ling, et al.
Publicado: (2018)

Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting
por: Piccinni, Carlo, et al.
Publicado: (2011)

Development and validation of method for defining conditions using Chinese electronic medical record
por: Xu, Yuan, et al.
Publicado: (2016)

An approach for medical event detection in Chinese clinical notes of electronic health records
por: Zhou, Xuesi, et al.
Publicado: (2019)

Toxicological evaluation of subchronic use of pioglitazone in mice
por: Elshama, Said Said, et al.
Publicado: (2016)

Using big data to improve cardiovascular care and outcomes in China: a protocol for the CHinese Electronic health Records Research in Yinzhou (CHERRY) Study
por: Lin, Hongbo, et al.
Publicado: (2018)

Developing and Validating Risk Scores for Predicting Major Cardiovascular Events Using Population Surveys Linked with Electronic Health Insurance Records
por: Chang, Hsing-Yi, et al.
Publicado: (2022)

Association of Pioglitazone With Major Adverse Cardiovascular Events, All-Cause Mortality, and Heart Failure Hospitalizations: A Systematic Review
por: Sheikh, Ibrahimkhalil M, et al.
Publicado: (2023)

Comparing Pioglitazone to Insulin with Respect to Cancer, Cardiovascular and Bone Fracture Endpoints, Using Propensity Score Weights
por: Vallarino, Carlos, et al.
Publicado: (2013)

Validity of Cardiovascular Disease Event Ascertainment Using Linkage to UK Hospital Records
por: Kivimäki, Mika, et al.
Publicado: (2017)

Data-Driven Information Extraction from Chinese Electronic Medical Records
por: Xu, Dong, et al.
Publicado: (2015)

Cardiovascular Event Rates in Statin-Treated Korean Patients with Cardiovascular Disease: Estimates from a Real-World Population Using Electronic Medical Record Data
por: Kwon, Osung, et al.
Publicado: (2021)

Mining comorbidities of opioid use disorder from FDA adverse event reporting system and patient electronic health records
por: Pan, Yiheng, et al.
Publicado: (2022)

A model based on electronic health records to predict transfusion events in on-pump cardiac surgery
por: Chen, Dong Xu, et al.
Publicado: (2023)

Adverse events recording in electronic health record systems in primary care
por: de Hoon, Sabine E. M., et al.
Publicado: (2017)

Developing a cardiovascular disease risk factor annotated corpus of Chinese electronic medical records
por: Su, Jia, et al.
Publicado: (2017)

Correction to: Cardiovascular Event Rates in Statin‑Treated Korean Patients with Cardiovascular Disease: Estimates from a Real‑World Population Using Electronic Medical Record Data
por: Kwon, Osung, et al.
Publicado: (2021)

Learning from Longitudinal Data in Electronic Health Record and Genetic Data to Improve Cardiovascular Event Prediction
por: Zhao, Juan, et al.
Publicado: (2019)

Pioglitazone: Indian perspective
por: Shukla, Rishi, et al.
Publicado: (2011)

An explainable artificial intelligence approach for predicting cardiovascular outcomes using electronic health records
por: Wesołowski, Sergiusz, et al.
Publicado: (2022)

Weight Change and the Onset of Cardiovascular Diseases: Emulating Trials Using Electronic Health Records
por: Katsoulis, Michail, et al.
Publicado: (2021)

POSA420 Trends in Thrombotic and Cardiovascular Events Among Hospitalized Patients with COVID-19 in the US: Findings from a Large Electronic Health Records Database
por: Icten, Z, et al.
Publicado: (2022)

A large language model for electronic health records
por: Yang, Xi, et al.
Publicado: (2022)

Major Adverse Cardiovascular Events in Coronary Type 2 Diabetic Patients: Identification of Associated Factors Using Electronic Health Records and Natural Language Processing
por: González-Juanatey, Carlos, et al.
Publicado: (2022)

Therapeutic effect and potential mechanism of pioglitazone in rats with severe acute pancreatitis
por: Hai, Wang, et al.
Publicado: (2017)

Pioglitazone reduces cardiovascular events and dementia but increases bone fracture in elderly patients with type 2 diabetes mellitus: a national cohort study
por: Yen, Chieh-Li, et al.
Publicado: (2023)

Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis
por: Yan, Huaqing, et al.
Publicado: (2018)

Time-sensitive clinical concept embeddings learned from large electronic health records
por: Xiang, Yang, et al.
Publicado: (2019)

Subphenotyping depression using machine learning and electronic health records
por: Xu, Zhenxing, et al.
Publicado: (2020)

Association between type 2 diabetes and cancer incidence in China: data in hospitalized patients from 2006 to 2013
por: Lu, Shan, et al.
Publicado: (2020)

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials
por: de Jong, Marit, et al.
Publicado: (2017)

Pioglitazone use and risk of bladder cancer: population based cohort study
por: Tuccori, Marco, et al.
Publicado: (2016)

Pioglitazone use and Parkinson’s disease: a retrospective cohort study in Taiwan
por: Wu, Hsiu-Feng, et al.
Publicado: (2018)

Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?
por: Carboni, Elena, et al.
Publicado: (2020)

Pioglitazone-Induced Acute Rhabdomyolysis
por: Slim, Raoudha, et al.
Publicado: (2009)

Investigation of the antibacterial activity of pioglitazone
por: Masadeh, Majed M, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_egl4hili3rir9s0g2ne2ac1ma6